OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, December 09, 2014

New Downloadable Slides: Adding Precision and Power to Progress in Ovarian Cancer Management





Sent from my MotoG

-----Original Message-----

From: "prIME Oncology" <info@primeoncology.org>
Sent: December 9, 2014 10:47 AM
To: sandipn@sympatico.ca
Subject: New Downloadable Slides: Adding Precision and Power to Progress in Ovarian Cancer Management

prIME Oncologyprofessional • independent • medical • education

Adding Precision and Power to Progress in Ovarian Cancer Management

Adding Precision and Power to Progress in Ovarian Cancer Management

prIME Oncology invites you to view downloadable slides from Adding Precision and Power to Progress in Ovarian Cancer Management, a symposium held at IGCS 2014 in Melbourne, Australia.

___________________________________________________________

Activity Features

icon
Downloadable Slides

» View Activity

preview

___________________________________________________________

Topics

Know your enemy: The impact of BRCA status on management of ovarian cancer
Clare Scott, MBBS, PhD

Keeping the lid on ovarian cancer: Targeted therapeutic approaches
Jonathan Ledermann, MD, FRCP

Platinum-sensitive relapsed ovarian cancer: New options on the horizon
Amit Oza, MD, FRCPC, MBBS

» View Activity

___________________________________________________________

Target Audience

This activity is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals involved in the treatment of patients with advanced ovarian cancer.

___________________________________________________________

Provider

This activity is provided by prIME Oncology.

ACCME

___________________________________________________________

Support

This educational activity is supported by AstraZeneca.

___________________________________________________________

Other prIME Activities

online activity
Advances and Challenges in the Management of Glioblastoma
online activity
The Changing Landscape of Chemotherapy for Nonsquamous Non-Small Cell Lung Cancer Treatment
online activity
Breathing New Life Into Sarcoma Management: Exploiting Hypoxia as a Therapeutic Target


icon Get the prIME Oncology app
iPhone | Android
google twitter youtube facebook linkedin
prIME Oncology

Schenkkade 50 | Suite 16 | 2595 AR The Hague | the Netherlands
2 Concourse Parkway | Suite 270 | Atlanta, Georgia | 30328 USA

This email was sent to sandipn@sympatico.ca. If you are no longer interested you can unsubscribe instantly.

Longwoods eLetter December 9, 2014 | If We Had a Magic Wand



Sundry interesting articles:

Sent from my MotoG

-----Original Message-----

From: "Longwoods Publishing" <longwoodseletters@longwoods.com>
Sent: December 9, 2014 11:53 AM
To: sandipn@sympatico.ca
Subject: Longwoods eLetter December 9, 2014 | If We Had a Magic Wand

Email not displaying correctly? View it in your browser. Forward this email to a colleague

Stay Connected
    Like Longwoods eLetter December 9, 2014 | If We Had a Magic Wand on Facebook share on Twitter

Quote

"I apologize because I didn't look hard enough, until now. I didn't look far enough. I didn't review papers from smaller labs in other countries doing some remarkable research, and I was too dismissive of the loud chorus of legitimate patients whose symptoms improved on cannabis." Dr. Sanjay Gupta Why I changed my mind on weed

Essays

If We Had a Magic Wand by Hugh MacLeod and Leslee Thompson
The second essay in the Ghost of Healthcare Hope series

Off the Cuff

"If the public had more information on the way doctors are compensated, they might have a more balanced perspective in terms of giving their views to the government during negotiations," says Tom Closson, former president of the Ontario Hospital Association. ...almost all suppliers of plasma products in the UK "have a track record of avoidable quality problems, in many cases resulting in deaths or serious chronic illness such as HIV." Read the essay Tories unlikely to stop Bill prohibiting paid plasma, but why are they even trying? by Rick Janson
While the public, some lawyers and even some politicians, especially in Quebec, are actively involved in the conversation about dying, what are oncologists, primary care and palliative care physicians and other allied health workers – the professionals who are most acutely involved with end-of-life care – doing to mobilize public and private conversations with their patients about PAD and euthanasia? 

...our research suggests that tens of thousands of incidents are slipping under the radar because those who witness poor care and try to report it are being told, in one particular case, to "mind their own business".

Part of the commitment to protect patients and the public should include the identification of risk, as well as the encouragement to voice concerns about the safety and relevance of our practices, policies and procedures in the workplace.

REGISTRATION OPEN: Ways & Means: Health Links – February 11, 2015: Ministries report. Patients reflect. Providers enlighten. Experts analyse. An interactive conference to define the opportunities and consider the possibilities to better care.

The Complete Library Online: Access to 50 issues of HealthcarePapers for the price of a one year subscription
Read the latest IHSPR Innovator newsletter

Last Week in Healthcare History
December 1, 1988: First World AIDS Day.
December 2, 1893: Royal Victoria Hospital officially opened by Governor General, Lord Aberdeen.
December 5, 1700: Montreal struck by influenza epidemic.


Longwoods' Events

      
Breakfast with the Chiefs – January 22, 2015
Dr. Jack Kitts, Dr. Barry McLellan, Dr. Kevin Smith and Leslee Thompson
Can innovation (1) improve care for patients (2) strengthen the healthcare system and (3) save money?
Register Now
Sponsored by Cerner CanadaPwCOrion HealthNational Research CorporationHIROCCanadian Foundation for Healthcare Improvement, and Rotman School of Management
REGISTER NOWFebruary 11, 2015. Ways & Means: Health Links – Ministries report. Patients reflect. Providers enlighten. Experts analyse. An interactive conference to define the opportunities and consider the possibilities to better care.

Join our Chairs:
Dr. Danielle Martin, Vice President, Medical Affairs and Health System Solutions, Women's College Hospital and
Dr. Sacha Bhatia, Director of the Institute for Health System Solutions and Virtual Care (WIHV) at Women's College Hospital.
More Information here.

Would you like to sign up your institution to become a Public Institution HealthcareBoard member and have unlimited number of your staff and board members attend a season of Breakfast with the Chiefs and receive discounts to HealthcareRounds? Contact Matthew Hart - mhart@longwoods.com

Our Editors Recommend

Healthcare Quarterly
Turning the Social Determinants of Health to Our Advantage: Policy Fundamentals for a Better Approach to Children's Health

HealthcarePapers
A Framework for Community-Oriented Primary Healthcare

Healthcare Policy
The Untold Story: Examining Ontario's Community Health Centres' Initiatives to Address Upstream Determinants of Health

Nursing Leadership
An Interview with Dr. Judith Shamian

World Health and Population
Health-seeking Behavior in Urban Delhi: An Exploratory Study

News


Conferences

December 10, 2014: Toronto, ON. IHSPR Policy Round
January 20, 2015: Webinar. Managing Multimorbidities
January 28, 2015: Webinar. Analyzing Data Over Time for Quality Improvement
February 5, 2015: Toronto, ON. Perspectives in Competency Assessment April 19-21, 2015: Richmond Hill, ON. 2015 HPCO Annual Conference - Call for abstracts deadline, November 17, 2014
May 19-22, 2015: Toronto, ON. Dorothy Wylie Health Leaders Institute
May 26-27, 2015: Ottawa, ON and Online. The Canadian Patient Safety Officer Course
May 26-27, 2015: Dartmouth, NS. The Atlantic Learning Exchange 2015
May 29-30, 2015: Toronto, ON. Global Telehealth 2015. Call for Papers deadline: December 15, 2014.
June 15-16, 2015: Charlottetown, PE. National Health Leadership Conference

Transitions

  • Michelle Floh to Entrepreneur in Residence, Alberta Innovates, Edmonton, AB
  • Cecily Wallace to Sr. Communications Advisor, Shared Services Canada, Ottawa, ON
  • Dr. Bert Lauwers to President and CEO, Ross Memorial Hospital, Lindsay, ON
  • Abdo Shabah to Vice President, Medical Affairs, Airmedic, Brossard, QC
  • Gary Kirk to Medical Officer of Health, Windsor-Essex County Health Unit, Windsor, ON
  • Helen Angus to Deputy Minister of Citizenship, Immigration and International Trade, Government of Ontario, Toronto, ON
  • Mary Jo Haddad to Board of Directors, Toronto-Dominion Bank, Toronto, ON
More | Send us your transitions.

Featured Careers

REMINDER - Are you a journal subscriber? Go to Longwoods.com and Create an Account. This eLetter is a weekly must read on national & local healthcare information, news, online essays & events. To Unsubscribe click on the link at the bottom of this page. The Longwoods™ eLetter may be re-distributed freely. Just forward this email message.

The Longwoods™ eLetter is normally published every Tuesday morning. Don't reply to this email letter. Instead, write the publisher.
Copyright 2014 Longwoods™ Publishing Corporation, publishers of academic, scientific and professional journals.

Please read our Privacy Statement. Longwoods™ Publishing Corporation, 260 Adelaide Street, East, #8, Toronto, Ontario, Canada M5A 1N1


Home | About Us | Subscriptions | Contact | Healthcare Jobs | Sign up for the Longwoods eLetter






This email was sent to sandipn@sympatico.ca
why did I get this?    unsubscribe from this list    update subscription preferences
Longwoods Publishing · 260 Adelaide St. E., Box 8 · Toronto, ON M5A 1N1 · Canada

Saturday, November 29, 2014

Genetic features of Lynch syndrome in the Israeli population



abstract

Inherited predisposition to breast cancer among African American women



abstract

Estrogen Biosynthesis and Action in Ovarian Cancer | Experimental Endocrinology



open access

 The review explains the role of estrogen in ovarian cancer and it gives an overview on ovarian cancer subtypes. Furthermore, enzymes active to synthesize and metabolize estrogens as well as estrogen signaling pathways are described. Strategies to target these pathways are discussed.

Potential Application of Curcumin and Its Analogues in the Treatment Strategy of Patients with Primary Epithelial Ovarian Cancer



Free Full-Text 


Training randomized trial recruiters to facilitate recruitment and informed consent by exploring patients' treatment preferences



 Full text 

........Several previous studies have tended to assume that patients’ treatment preferences are simple and static entities that can be easily defined and measured [4,10]. However, there is also a small body of research that shows that preferences are complex, multifaceted, and changeable entities that can be based on incomplete or inaccurate information [11-16]. .....

Friday, November 28, 2014

Up-to-dateness of reviews is often neglected in overviews: a systematic review



open access

 1. Introduction

What is new?

Key findings

The mean publication lag per review was more than 5 years.
Only one in four overviews considered up-to-dateness.
No overview systematically investigated whether an update was necessary.

What this adds to what was known?

This is the first systematic analysis of up-to-dateness in overviews.
We developed recommendations to produce up-to-date overviews.

What is the implication and what should change now?

Authors should analyze whether the underlying evidence of systematic reviews (SRs) is still up-to-date when conducting overviews.
Authors should search for primary studies not included in SRs, if needed
Keeping current with the scientific literature is a very challenging task for researchers but even more so for health professionals as the amount of published literature in medical science is rapidly rising. Eleven systematic reviews (SRs) and 75 trials need to be read every day to keep up-to-date, when just considering the publications listed in MEDLINE [1].
This huge amount of literature has led reviewers to perform evidence syntheses on reviews instead of primary studies that are often called overviews (of reviews), review of reviews, and umbrella reviews [2]........

New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials, Immunotherapy



abstract

 Aim: This study aimed to derive meaningful parameters for immune monitoring during cancer vaccine development by analysis of the literature.  
Methods: This retrospective study was based on analysis of clinical trials registered at ClinicalTrials.gov and published data available on PubMed.  
Results: The most common sample evaluated in immune monitoring was peripheral blood. All trials employed ELISA for detecting a humoral immune response; however, cellular immune assays were not used across trials. Most cellular immune assays failed to correlate with clinical outcome, although results of other methods did. Conclusion: Standardization of the cellular immune assays across trials is important for predicting the effects of therapeutic cancer vaccines when considering the reliability and characteristics of the methods. Currently, assays mostly target detection of T-cell function, such as proliferation and cytokine release; however, T-cell phenotype analysis in peripheral blood and/or tumor sites may also be considered in the future.

Wednesday, November 26, 2014

InVitae Poster Expands Data on Hereditary Cancer Panel Testing - BRCA1/2 / Lynch Syndrome



GenomeWeb

Recalls, Market Withdrawals, & Safety Alerts > Natura Pet Recalls



 Natura Pet Recalls 5 Lots of Dry Cat and Dry Ferret Food due to Vitamin Insufficiency

Prognostic Significance of Sugarbaker's Peritoneal Cancer Index for the operability of ovarian carcinoma



abstract


INTRODUCTION:

This study aimed to investigate Sugarbaker's peritoneal cancer index (PCI) as a prognostic indicator for the resectability of ovarian carcinoma (OC), as depicted in the study using the completeness of cytoreduction score (CCS).Currently, the intraoperative assessment of operability in OC surgery is primarily a subjective measurement that is dependent on the surgeon.

METHODS:

The retrospective data from 98 patients with OC International Federation of Gynecology and Obstetrics (FIGO) III to IV who had received surgery between January 2010 and December 2011 were analyzed. The PCI and the CCS were determined retrospectively using surgical reports, histological findings, and intraoperative photographic documentation. Receiver operating characteristic curves and ordinal regression were applied to evaluate the predictability of CCS using the PCI.

RESULTS:

Of 98 patients, 80 (81.6%) were staged FIGO III and 18 (18.4%) FIGO IV. A statistically significant correlation was demonstrated between the PCI and CCS (P < 0.01).......

CONCLUSIONS:

The PCI more precisely defined the heterogeneous group of patients with OC FIGO III. The PCI provided objectivity and reproducibility, and it seems to be a possible prognostic indicator for OC resectability.

worth reading: Looking For Light in a Dark Room - note references to YAC/clinical trials/Canada....



 Cancer Knowledge Network

 .....The AIDS movement, which changed the fates of thousands of dying people was not built from positive thinking.  Change happened because people were angry. Access to drugs came about because people stood up and said “this is not acceptable”. It is not acceptable that those of us with advanced disease cannot access the drugs we need because of bureaucracy and the screwed up drug trial system. It is not acceptable that many provinces do not cover drugs like oral chemo.  It is not acceptable that as an act to save our lives some of us have to go out of country to access up and coming drug trials.  It is not acceptable that we are dying.  Empowerment and positive thinking is important but so is addressing the dark side of cancer.  Young adult organizations need to decide whether or not they will take a stand with those of us who are dying and living chronically.  They need to explore how they can contribute to the empowerment of those of us who cannot get past our cancer experience. They need to help end isolation and take affirmative action towards change.

Genetics of Skin Cancer (references to BRCA (BAP1) and BRCA2



National Cancer Institute


BRCA-Associated Protein 1 (BAP1) BRCA-associated protein 1 (BAP1) has recently emerged as a gene implicated both in sporadic and hereditary melanomas......

BRCA2
The Breast Cancer Linkage Consortium found that mutations in BRCA2 were associated with a relative risk of melanoma of 2.58 (95% CI, 1.3–5.2).[155] A second study reported a similar increase in risk, although the result fell short of statistical significance.[156] In contrast, another large cohort study of BRCA2 mutation carriers in the Netherlands showed a decreased risk of melanoma; however, the expected incidence of melanoma was rare in this population, and this result reflects a difference of only two melanoma cases.[157] Ashkenazi Jewish melanoma patients have not been shown to have an increased prevalence of the three founder mutations in BRCA1 and BRCA2 that are commonly found in this population.[158] Overall, the evidence for increased risk of melanoma in the BRCA2 population is inconsistent at this time.
(Refer to the BRCA1 and BRCA2 section in the PDQ summary on Genetics of Breast and Ovarian Cancer for more information.)


Google and Women's Health-Related Issues: What Does the Search Engine Data Reveal?



abstract

pdf  (requires registration - free - to view full text)

OBJECTIVES:

Identifying the gaps in public knowledge of women's health related issues has always been difficult. With the increasing number of Internet users in the United States, we sought to use the Internet as a tool to help us identify such gaps and to estimate women's most prevalent health concerns by examining commonly searched health-related keywords in Google search engine.

METHODS:

We collected a large pool of possible search keywords from two independent practicing obstetrician/gynecologists and classified them into five main categories (obstetrics, gynecology, infertility, urogynecology/menopause and oncology), and measured the monthly average search volume within the United States for each keyword with all its possible combinations using Google AdWords tool.

RESULTS:

We found that pregnancy related keywords were less frequently searched in general compared to other categories with an average of 145,400 hits per month for the top twenty keywords. Among the most common pregnancy-related keywords was "pregnancy and sex' while pregnancy-related diseases were uncommonly searched. HPV alone was searched 305,400 times per month. Of the cancers affecting women, breast cancer was the most commonly searched with an average of 247,190 times per month, followed by cervical cancer then ovarian cancer.

CONCLUSION:

The commonly searched keywords are often issues that are not discussed in our daily practice as well as in public health messages. The search volume is relatively related to disease prevalence with the exception of ovarian cancer which could signify a public fear.

Amgen Ends Gastric Cancer Drug Studies on Safety Review - Amgen/Trebananib/ovarian



Analyst Blog

....We note that Amgen stumbled with its oncology pipeline earlier this month as well when its experimental ovarian cancer treatment, trebananib, failed to meet the secondary endpoint of overall survival in a late-stage study. Although trebananib had achieved the primary endpoint of the study, overall survival is an important criterion for gaining FDA approval. Moreover, the rate of discontinuation due to adverse events was much higher in the trebananib arm compared to the control arm (20% versus 7%).....

Tuesday, November 25, 2014

On vitamin D, the so-called experts have it wrong, U.K. researcher says (re: the Lancet)



media

.....However, The Lancet, the world’s best-known medical journal, recently suggested in an editorial that most of the benefits of vitamin D advanced by scientific studies are a “myth.” It says people tend to have low vitamin D when they are ill because they do not go outdoors very much.
Most of The Lancet’s trials have used low doses of vitamin D
This was also the view presented in papers published in The Lancet by two teams, Philippe Autier of the International Prevention Research Institute, Lyon, and Mark Bolland of the Department of Medicine, University of Auckland.
They argue that clinical trials of vitamin D have failed to show any clear benefit. However, most of the trials have used low doses of the vitamin. Professor Michael Holick, pioneer of vitamin D research at Boston University, says 4,000 units per day is required to give an optimum level of the vitamin in the blood, enough to prevent disease. A number of clinical trials relied on by The Lancet editorial and its authors used a daily dose of just 400 units.....

Blurring of boundaries in the doctor–patient relationship : The Lancet Oncology



 Note: too bad open access is not available on this one

extract only

Blurring of boundaries in the doctor—patient relationship


Oncology is a specialty that can be enormously rewarding but is fraught with many challenges. Young oncologists have to master dealing with anxious patients who are facing a life-threatening disease; conveying the true prognosis; discussing the complexity of modern treatments; and explaining the unavailability of some drugs, the side-effects of treatment, and likely therapeutic aims. Evidence-based courses have been shown to help oncologists to communicate all these issues in a clear, honest, an ...

Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer



abstract

 Objective
The objective of the study was to analyze in a large series of unresectable advanced ovarian cancer (AOC) patients the prognostic role of pathological response to neoadjuvant chemotherapy (NACT).....

Outcomes from ultrasound follow-up of small complex adnexal masses in women over 50



abstract

Objective

The discovery of a complex adnexal mass in an older woman often raises concern for cancer. We evaluate outcomes for a large population-based cohort of women older than age 50 years with a small complex adnexal mass reported on ultrasound, without elevated CA125 or other evidence of malignancy, including time to detection of malignancy and stage at diagnosis for those initially observed...........

Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients (extracolonic cancers)



abstract

 Conclusion A significant difference in extracolonic Lynch syndrome-associated cancer was evident between suspected familial colorectal cancer type X and Lynch syndrome.

(Lynch Syndrome patients) Clinical and prognostic factors for renal parenchymal, pelvis, and ureter cancers in SEER registries: Collaborative stage data collection system, version 2 - Altekruse - 2014 - Cancer - Wiley Online Library



 Note: not specific to genetics (eg. Lynch Syndrome)

SEER registries: Collaborative stage data collection system, version 2 (open access)

Renal pelvis and ureter

Kidney and renal pelvis cancers often are combined for the purposes of cancer surveillance, with ureter cancer presented separately. Renal pelvis and ureter cancers share CSv2 SSFs, however, and are grouped in the AJCC stage coding schema; cancers of the renal parenchyma have a different set of SSFs.[3] Findings for both renal pelvis and ureter cancers are presented in this report.
The SSFs for these cancer sites are World Health Organization or International Society of Urological Pathology (WHO/ISUP) grade[31] (SSF1) and depth of renal parenchymal invasion (SSF2).[32] Both SSFs for these sites affect prognosis. SSF1 for renal pelvis and ureter is the WHO/ISUP grade, a 2-grade system (low and high grade). This grading system was proposed by ISUP in 1998 and adopted by WHO in 2004 to better classify the tumor grade for urothelial carcinomas of the renal pelvis, ureter, bladder, and urethra.[33, 34] The strengths of the WHO/ISUP grade's clear-cut criteria and the elimination of subjective and arbitrary interpretation have greatly improved the ambiguous language that marked the 1973 WHO system.[35] SSF2, depth of renal parenchymal invasion, records the depth of tumor invasion into the renal parenchyma in millimeters as documented in the pathology report.

 With respect to renal pelvis and ureter cancer, a high WHO/ISUP grade (SSF1) is independently associated with worse outcomes in surgical cases.[42] WHO/ISUP grade was known for 85% of cases with resection. SSF2 (depth of renal parenchymal invasion as a marker of recurrence) also has been validated[43]; however, most values for this variable were unknown. Additional SSFs for renal pelvis and ureter cancer might be considered based on prognostic value. Promising markers for these understudied cancers include tumor architecture,[44, 45] multifocality,[46] and the presence of concomitant carcinoma in situ.[47] In some studies,[48] tumor location (ie, ureter, renal pelvis, or both) has also been suggested to have prognostic value.

#ovariancancers

A quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines



abstract

Editorial: Screening for Vitamin D Deficiency: Is the Goal Disease Prevention or Full Nutrient Repletion?



Editorial open access

Screening for Vitamin D Deficiency: A Systematic Review for the U.S. Preventive Services Task ForceScreening for Vitamin D Deficiency | Annals of Internal Medicine



open access


Background: Vitamin D deficiency has been associated with adverse health outcomes.
Purpose: To systematically review benefits and harms of vitamin D screening in asymptomatic adults.
Data Sources: Ovid MEDLINE (through the third week of August 2014), Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews.
Study Selection: Randomized trials of screening for and treatment of vitamin D deficiency and case–control studies nested within the Women's Health Initiative.
Conclusion: Treatment of vitamin D deficiency in asymptomatic persons might reduce mortality risk in institutionalized elderly persons and risk for falls but not fractures.

Monday, November 24, 2014

Genetic Testing Fact Sheet - National Cancer Institute



NCI

 3. What genetic tests are available for cancer risk?

More than 50 hereditary cancer syndromes have been described. The majority of these are caused by highly penetrant mutations that are inherited in a dominant fashion. The list below includes some of the more common inherited cancer syndromes for which genetic testing is available, the gene(s) that are mutated in each syndrome, and the cancer types most often associated with these syndromes.

Hereditary breast cancer and ovarian cancer syndrome
  • Genes: BRCA1, BRCA2
  • Related cancer types: Female breast, ovarian, and other cancers, including prostate, pancreatic, and male breast cancer
Li-Fraumeni syndrome
  • Gene: TP53
  • Related cancer types: Breast cancer, soft tissue sarcoma, osteosarcoma (bone cancer), leukemia, brain tumors, adrenocortical carcinoma (cancer of the adrenal glands), and other cancers
Cowden syndrome (PTEN hamartoma tumor syndrome)
  • Gene: PTEN
  • Related cancer types: Breast, thyroid, endometrial (uterine lining), and other cancers
Lynch syndrome (hereditary nonpolyposis colorectal cancer)
  • Genes: MSH2, MLH1, MSH6, PMS2, EPCAM
  • Related cancer types: Colorectal, endometrial, ovarian, renal pelvis, pancreatic, small intestine, liver and biliary tract, stomach, brain, and breast cancers
Familial adenomatous polyposis
  • Gene: APC
  • Related cancer types: Colorectal cancer, multiple non-malignant colon polyps, and both non-cancerous (benign) and cancerous tumors in the small intestine, brain, stomach, bone, skin, and other tissues
Retinoblastoma
  • Gene: RB1
  • Related cancer types: Eye cancer (cancer of the retina), pinealoma (cancer of the pineal gland), osteosarcoma, melanoma, and soft tissue sarcoma
Multiple endocrine neoplasia type 1 (Wermer syndrome)
  • Gene: MEN1
  • Related cancer types: Pancreatic endocrine tumors and (usually benign) parathyroid and pituitary gland tumors
Multiple endocrine neoplasia type 2
Von Hippel-Lindau syndrome
  • Gene: VHL
  • Related cancer types: Kidney cancer and multiple noncancerous tumors, including pheochromocytoma

HealthNewsReview.org - Independent Expert Reviews of News Stories



Independent Expert Reviews of News Stories

OUR CRITERIA FOR WHAT USERS NEED IN STORIES

On treatments, tests, products, procedures
Visit each link to hear from patients and doctors about why these matter, and to see Thumbs up and Down story examples.


11 country survey: International Survey of Older Adults Finds Shortcomings in Access, Coordination, and Patient-Centered Care



The Commonwealth Fund

About the Study

The 2014 Commonwealth Fund International Health Policy Survey of Older Adults was conducted by phone from March through May 2014. More than 15,000 people age 65 or older took part in Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States......

Nurturing Empathy: An Oncologist Looks at Medicine and Himself



The Oncologist (pdf)

Empathy in medicine matters. I should know—I have been
a practicing oncologist for 35 years—but it was only when, in
a matter of seconds, I went from doctor to patient that I
grasped its true significance.......

Friday, November 21, 2014

Recent progress in the treatment and prevention of cancer-related lymphedema - Shaitelman - 2014 - CA: A Cancer Journal for Clinicians - Wiley Online Library



open access


Lymphedema Beyond Patients With Breast Cancer

Patients with other solid tumors requiring treatment that adversely affects lymphatic function are also at significant risk of developing lymphedema. Unfortunately, relatively few studies have investigated lymphedema in these patient populations. For example, a recent systematic review identified only 47 studies that assessed non-breast cancer-related lymphedema, and most of those studies were retrospective.[50] The following subsections provide an overview of the current body of published literature regarding the incidence of lymphedema as a result of the treatment of nonbreast malignancies......

 One recent systematic review highlighted several areas in the delivery and cost of lymphedema treatment that might benefit from changes in health policy. Stout et al[239] identified 8 articles about health care delivery models and 6 articles about economic and cost analyses. They found that although evidence-based care for the diagnosis and treatment of lymphedema is limited, much of the burden to facilitate diagnosis and referral for effective care is placed on the patient. The authors also found that, compared with patients who do not have lymphedema, patients with lymphedema have significantly higher hospitalization rates, higher rates of medical services use, lower QOL, and significantly higher indirect costs. However, the study had a low level of evidence and yielded only speculative findings.

Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?



open access

 Abstract

 Next-generation sequencing studies have provided further evidence to support the notion that cancer is a disease characterized by Darwinian evolution. Today, we often fail to capture this evolution and treatment decisions, even in the metastatic setting, are often based on analysis of primary tumor diagnosed years ago. Currently, this is considered a major reason for treatment failures in cancer care. Recent technological advances in the detection and characterization of circulating tumor cells and circulating tumor DNA might address this and allow for treatment tailoring based on real-time monitoring of tumor evolution. In this review, we summarize the most important recent findings in the field, focusing on challenges and opportunities in moving these tools forward in clinical practice......
  1. Ann Oncol 25 (12): 2304-2313. doi: 10.1093/annonc/mdu480
  1. All Versions of this Article:
    1. mdu480v1
    2. 25/12/2304 most recent

Prioritizing targets for precision cancer medicine



open access (technical)

 Abstract
The implementation of cancer genomic testing into the clinical setting has brought major opportunities. However, as our understanding of cancer initiation, maintenance and progression improves through detailed cancer genomic studies, the challenges associated with driver identification and target classification in the clinical setting become clearer. Here, we review recent insights into cancer genomic testing in the clinical setting, and suggest a target classification approach that considers the levels of evidence supporting the prioritization of tumour drivers for therapeutic targeting in light of complex cancer clonal and sub-clonal structures and clinical successes and failures in the field. We argue that such classification approaches, together with transparent reporting of both positive and negative clinical data and continued research to identify the sub-clonal dynamics of driver events during the disease course, will facilitate inter-trial comparisons, optimize patient informed consent and provide a critically balanced evaluation of genomic testing in clinical practice....... 

This Article

  1. Ann Oncol 25 (12): 2295-2303. doi: 10.1093/annonc/mdu478
  1. All Versions of this Article:
    1. mdu478v1
    2. 25/12/2295 most recent

In year two, MD Anderson Moon Shots Program begins to spin off innovation | MD Anderson Cancer Center



media

Personalized surgery
A new protocol for determining which ovarian cancer patients should proceed to surgery upfront and which need presurgical chemotherapy has radically increased the rate of complete surgical removal of tumors, an accomplishment that improves patient survival.

Under the MD Anderson algorithm developed by the moon shot, a patient receives a less-invasive laparoscopic evaluation, during which two surgeons independently rank the cancer’s spread to other organs. The resulting score guides the treatment decision.

Previously, virtually all new patients had surgery to explore the extent of disease and to remove as much of it as possible. Worldwide, this practice results in 20 to 30 percent of these patients achieving “complete gross resection.” In the first 155 cases in which the algorithm was followed, complete resection was achieved 89 percent of the time......

MD Anderson’s David M. Gershenson, MD, Receives IGCS’s Award for Excellence in Gynecologic Oncology



David M. Gershenson

Houston, Texas -- For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society’s (IGCS) Award of Excellence.......